---
title: ""
execute:
echo: false
eval: false
---
::: {.gallery-header}
# arframe TFL Gallery
Submission-ready clinical trial tables and listings. Every example runs — pick a tab, copy the code.
:::
## Tables
::: {.tlg-grid}
::: {.tlg-card}
[TABLE · STUDY POPULATION]{.card-type}
### [Demographics Summary](tables/demographic.qmd)
[Continuous + categorical statistics by treatment arm with Total column. Age, age group, sex, race, ethnicity. Group headers, blank-after, decimal alignment.]{.card-desc}
::: {.card-tags}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::
::: {.tlg-card}
[TABLE · STUDY POPULATION]{.card-type}
### [Medical History](tables/medical-history.qmd)
[Medical history by SOC and preferred term. Hierarchical layout with indentation.]{.card-desc}
::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[cards]{.tag .tag-cards}
:::
:::
::: {.tlg-card}
[TABLE · STUDY POPULATION]{.card-type}
### [Prior Medication](tables/prior-medication.qmd)
[Prior medications by medication class and preferred name. Hierarchical layout.]{.card-desc}
::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[cards]{.tag .tag-cards}
:::
:::
::: {.tlg-card}
[TABLE · STUDY POPULATION]{.card-type}
### [Subject Disposition](tables/disposition.qmd)
[Screening, randomization, treatment completion, and reasons for discontinuation.]{.card-desc}
::: {.card-tags}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::
::: {.tlg-card}
[TABLE · STUDY POPULATION]{.card-type}
### [Disposition - Screening](tables/disposition-screening.qmd)
[Screened, screen failures, and enrolled subject counts.]{.card-desc}
::: {.card-tags}
[decimal]{.tag .tag-decimal}
:::
:::
::: {.tlg-card}
[TABLE · STUDY POPULATION]{.card-type}
### [Disposition - End of Study](tables/disposition-eos.qmd)
[End of study status — completed, discontinued, ongoing.]{.card-desc}
::: {.card-tags}
[decimal]{.tag .tag-decimal}
:::
:::
::: {.tlg-card}
[TABLE · STUDY CONDUCT]{.card-type}
### [Enrollment by Country and Site](tables/enrollment-country.qmd)
[Enrollment counts by country with site-level detail. Hierarchical layout.]{.card-desc}
::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[decimal]{.tag .tag-decimal}
:::
:::
::: {.tlg-card}
[TABLE · STUDY POPULATION]{.card-type}
### [Analysis Populations](tables/analysis-populations.qmd)
[Summary of analysis populations — enrolled, safety, ITT/FAS.]{.card-desc}
::: {.card-tags}
[decimal]{.tag .tag-decimal}
:::
:::
::: {.tlg-card}
[TABLE · SAFETY]{.card-type}
### [Death Summary](tables/death-summary.qmd)
[Deaths by treatment arm with cause-of-death breakdown.]{.card-desc}
::: {.card-tags}
[decimal]{.tag .tag-decimal}
:::
:::
::: {.tlg-card}
[TABLE · SAFETY]{.card-type}
### [AE by SOC and Preferred Term](tables/ae-soc-pt.qmd)
[Hierarchical SOC/PT structure. Bold SOC rows, indented PTs, frequency sorting.]{.card-desc}
::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::
::: {.tlg-card}
[TABLE · SAFETY]{.card-type}
### [AEs Related to Study Drug](tables/ae-related.qmd)
[Treatment-emergent AEs related to study drug (possible/probable) by SOC and PT.]{.card-desc}
::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[cards]{.tag .tag-cards}
:::
:::
::: {.tlg-card}
[TABLE · SAFETY]{.card-type}
### [Common Adverse Events](tables/ae-common.qmd)
[Preferred terms occurring at ≥5% in any treatment arm. Sorted by frequency.]{.card-desc}
::: {.card-tags}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::
::: {.tlg-card}
[TABLE · SAFETY]{.card-type}
### [AE by Grade/Intensity](tables/ae-grade.qmd)
[Adverse events by maximum CTCAE grade per treatment arm.]{.card-desc}
::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[decimal]{.tag .tag-decimal}
:::
:::
::: {.tlg-card}
[TABLE · SAFETY]{.card-type}
### [Overall Safety Summary](tables/ae-overall.qmd)
[Any TEAE, SAEs, deaths, discontinuations due to AE.]{.card-desc}
::: {.card-tags}
[decimal]{.tag .tag-decimal}
:::
:::
::: {.tlg-card}
[TABLE · SAFETY]{.card-type}
### [AE with Event Counts](tables/ae-event-counts.qmd)
[SOC/PT table showing both subject counts and event counts per term.]{.card-desc}
::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::
::: {.tlg-card}
[TABLE · SAFETY]{.card-type}
### [Exposure-Adjusted Adverse Events](tables/ae-exposure-adjusted.qmd)
[AE incidence rates per 100 patient-years by SOC and preferred term.]{.card-desc}
::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[decimal]{.tag .tag-decimal}
:::
:::
::: {.tlg-card}
[TABLE · SAFETY]{.card-type}
### [Adverse Events by Subgroup](tables/ae-subgroup.qmd)
[Treatment-emergent AE summary stratified by treatment arm and age subgroup.]{.card-desc}
::: {.card-tags}
[decimal]{.tag .tag-decimal}
[split]{.tag .tag-split}
:::
:::
::: {.tlg-card}
[TABLE · SAFETY]{.card-type}
### [Serious AEs by SOC and PT](tables/ae-sae-soc-pt.qmd)
[Serious adverse events by system organ class and preferred term. Hierarchical with bold SOC rows.]{.card-desc}
::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[cards]{.tag .tag-cards}
:::
:::
::: {.tlg-card}
[TABLE · SAFETY]{.card-type}
### [AEs Leading to Discontinuation](tables/ae-discontinuation.qmd)
[Treatment-emergent AEs leading to study drug discontinuation by SOC and PT.]{.card-desc}
::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[cards]{.tag .tag-cards}
:::
:::
::: {.tlg-card}
[TABLE · SAFETY]{.card-type}
### [Vital Signs](tables/vitals.qmd)
[One row per treatment group at each visit, Value and Change from Baseline statistics as columns. Page-by parameter with spanning headers.]{.card-desc}
::: {.card-tags}
[page_by]{.tag .tag-pageby}
[decimal]{.tag .tag-decimal}
[split]{.tag .tag-split}
:::
:::
::: {.tlg-card}
[TABLE · EXTENT OF EXPOSURE]{.card-type}
### [Concomitant Medications](tables/conmeds.qmd)
[Medications by ATC class and preferred name. Hierarchical with bold category rows.]{.card-desc}
::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[decimal]{.tag .tag-decimal}
:::
:::
::: {.tlg-card}
[TABLE · EXTENT OF EXPOSURE]{.card-type}
### [Extent of Exposure](tables/exposure.qmd)
[Study drug exposure: total duration, total dose, average daily dose with duration categories.]{.card-desc}
::: {.card-tags}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::
::: {.tlg-card}
[TABLE · SAFETY]{.card-type}
### [Laboratory Results - Chemistry](tables/lab-chemistry.qmd)
[Chemistry panel summary by visit. Per-variable decimal precision showcase with `fr_wide_ard()`.]{.card-desc}
::: {.card-tags}
[decimal]{.tag .tag-decimal}
[page_by]{.tag .tag-pageby}
[cards]{.tag .tag-cards}
:::
:::
::: {.tlg-card}
[TABLE · SAFETY]{.card-type}
### [Laboratory Marked Abnormalities](tables/lab-abnormalities.qmd)
[Subjects with notable high/low laboratory values by chemistry parameter and treatment arm.]{.card-desc}
::: {.card-tags}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::
::: {.tlg-card}
[TABLE · SAFETY]{.card-type}
### [Electrocardiogram Summary](tables/ecg-summary.qmd)
[Worst post-baseline QTc categories and maximum increase from baseline by treatment arm.]{.card-desc}
::: {.card-tags}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::
::: {.tlg-card}
[TABLE · EFFICACY]{.card-type}
### [Time to Event Summary](tables/tte-summary.qmd)
[Overall survival with KM median, quartiles, hazard ratio, and log-rank p-value.]{.card-desc}
::: {.card-tags}
[decimal]{.tag .tag-decimal}
:::
:::
::: {.tlg-card}
[TABLE · EFFICACY]{.card-type}
### [Best Overall Response](tables/efficacy-bor.qmd)
[BOR categories with derived ORR and DCR rates. Oncology efficacy endpoint summary.]{.card-desc}
::: {.card-tags}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::
:::
## Figures
::: {.tlg-grid}
::: {.tlg-card}
[FIGURE · EFFICACY]{.card-type}
### [Kaplan-Meier Plot](figures/km-plot.qmd)
[Progression-free survival curves by treatment arm with number-at-risk table.]{.card-desc}
::: {.card-tags}
:::
:::
::: {.tlg-card}
[FIGURE · EFFICACY]{.card-type}
### [Swimmer Plot](figures/swimmer-plot.qmd)
[Subject treatment duration with response markers over time.]{.card-desc}
::: {.card-tags}
:::
:::
::: {.tlg-card}
[FIGURE · EFFICACY]{.card-type}
### [Waterfall Plot](figures/waterfall-plot.qmd)
[Best percentage change from baseline in target lesion size per subject.]{.card-desc}
::: {.card-tags}
:::
:::
:::
## Listings
::: {.tlg-grid}
::: {.tlg-card}
[LISTING · SAFETY]{.card-type}
### [Adverse Event Listing](listings/ae-listing.qmd)
[Subject-level AE listing with SOC, PT, severity, onset, duration, outcome, relationship.]{.card-desc}
::: {.card-tags}
[listing]{.tag .tag-listing}
:::
:::
::: {.tlg-card}
[LISTING · STUDY POPULATION]{.card-type}
### [Demographic Characteristics](listings/demog-listing.qmd)
[Subject-level demographics — age, sex, race, ethnicity, weight, height.]{.card-desc}
::: {.card-tags}
[listing]{.tag .tag-listing}
:::
:::
::: {.tlg-card}
[LISTING · SAFETY]{.card-type}
### [Medical History Listing](listings/mh-listing.qmd)
[Subject-level medical history with SOC, preferred term, reported term, category, and severity.]{.card-desc}
::: {.card-tags}
[listing]{.tag .tag-listing}
[page_by]{.tag .tag-pageby}
:::
:::
::: {.tlg-card}
[LISTING · SAFETY]{.card-type}
### [Vital Signs Listing](listings/vs-listing.qmd)
[Subject-level vital signs by visit with baseline and change values.]{.card-desc}
::: {.card-tags}
[listing]{.tag .tag-listing}
[page_by]{.tag .tag-pageby}
:::
:::
::: {.tlg-card}
[LISTING · SAFETY]{.card-type}
### [Laboratory Test Results Listing](listings/lab-listing.qmd)
[Subject-level chemistry lab results with value, baseline, change, and normal range flag.]{.card-desc}
::: {.card-tags}
[listing]{.tag .tag-listing}
[decimal]{.tag .tag-decimal}
[page_by]{.tag .tag-pageby}
:::
:::
::: {.tlg-card}
[LISTING · EXTENT OF EXPOSURE]{.card-type}
### [Concomitant Medications Listing](listings/conmeds.qmd)
[Subject-level concomitant medications with ATC class, dose, route, and dates.]{.card-desc}
::: {.card-tags}
[listing]{.tag .tag-listing}
[page_by]{.tag .tag-pageby}
:::
:::
:::